Manfred Windisch, PhD, NeuroScios GmbH, Graz, Austria, discusses the direction of disease-modifying therapeutic development in Alzheimer’s disease. He highlights the finding that significant reduction in amyloid burden in the brain has a moderate effect on cognition, and the impact this has had on the field. Dr Windisch also discusses the potential of combination therapies — combining disease-modifying therapies with symptomatic treatments to see if this results in faster improvement in function. Finally, he touches on the need to determine whether existing treatments work differently in the new disease population of patients who present with Alzheimer’s disease without amyloid in the brain. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
